****

**Physician team**

**Robert Arceci, MD, PhD**

**Co-Director**

**Ronald A. Matricaria Institute of Molecular Medicine at Phoenix Children’s Hospital**

Dr. Robert Arceci joined the Ronald A. Matricaria Institute of Molecular Medicine with a belief that a new approach was needed to accelerate finding cures for children and adolescents with cancer.

He comes to the institute from Johns Hopkins School of Medicine, where he serves as the King Fahd Professor of Pediatric Oncology and co-director of the Michael Garil Leukemia Survivors Program, and previously served as director of pediatric oncology. Before that, he was director of pediatric hematology/oncology at Cincinnati Children’s Hospital and was on the faculty at Harvard Medical School, the Dana Farber Cancer Institute and Boston Children’s Hospital.

Arceci is consideredan international authority in pediatric oncology, particularly in the diagnosis and treatment of leukemia and histiocytic disorders, and, more recently in high-risk sarcomas. He has been at the forefront of implementing clinical applications of molecular medicine discoveries in oncology. His laboratory research focuses on the elucidation of fundamental mechanisms of cell growth, survival and senescence during normal and neoplastic development, as well as in the identification of novel pathways for therapeutic targeting of leukemia and solid tumors. Active areas of his work include epigenetic mechanisms during development, cancer pathogenesis and senescence along with targeted immunotherapies.

Arceci earned a bachelor’s degree from Trinity College, and doctorate and medical degrees from the University of Rochester. He completed his residency in pediatrics and fellowship in pediatric hematology/oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

Arceci is a member of numerous scientific and medical societies and a fellow of the American Association for the Advancement of Science. He also is the recipient of a multitude of prestigious honors and awards.

Arceci serves as the founding Editor-in-Chief of *Pediatric Blood and Cancer*, and as editor of several textbooks, including *Pediatric Hematology*. He originated the Emmy Award-winning movie *A Lion in the House* about childhood cancer by documentary filmmakers Steven Bognar and Julia Reichert.

**Timothy Triche, MD, PhD**

**Co-Director**

**Ronald A. Matricaria Institute of Molecular Medicine at Phoenix Children’s Hospital**

Dr. Timothy Triche comes to the Ronald A. Matricaria Institute of Molecular Medicine with expertise in DNA sequencing, the process of determining the precise order of nucleotides – the building blocks of DNA and RNA.

Triche has served in a variety of roles at Children’s Hospital Los Angeles, including as director of the Center for Personalized Medicine and chairman of the Department of Pathology & Laboratory Medicine, and pathologist-in-chief over the past 24 years at the Keck School of Medicine of the University of Southern California, where he is professor of Pathology and Pediatrics. Prior to that, he was a section chief in the Laboratory of Pathology at the National Cancer Institute, National Institutes of Health, for 14 years, where he developed specialized cancer diagnostics.

Triche’s current research is centered on the integration of genomic data with tumor biology that predicts diagnosis, prognosis and response to targeted therapeutic agents, with a particular focus on non-coding RNA. Triche’s other major areas of research interest include biology and molecular genetics of childhood and adult cancer; correlation of sarcoma gene expression profiles and clinical outcomes; identification and validation of diagnostic, prognostic and therapeutic gene targets; mechanisms of action of chimeric genes in childhood sarcomas; the development of systemic targeted small molecule and siRNA cancer therapy; and pathogenesis of age-related macular degeneration.

Triche earned a bachelor’s degree from Cornell University, and doctorate and medical degrees from Tulane University. He completed residencies in pathology and surgical pathology at Washington University Medical School/Barnes Hospital in St. Louis.

During his more than 40 years in medicine, Triche has served on numerous national committees of the Children’s Oncology Group, including group vice chair for translational research. He also was a member of the Children’s Cancer Group, where he was pathology discipline chair, as well as a member of the transition committee that formed COG and CCG, among other medical research groups. Additionally, he was a member of the intergroup Rhabdomyosarcoma Study Group and a founding member of the Association of Molecular Pathology.

**Daniel D. Von Hoff, MD, FACP**

**Physician-in-chief, Director of Translational Research**

**Translational Genomics Research Institute**

**Chief Scientific Officer, US Oncology, Scottsdale Healthcare Clinical Research Institute**

**Clinical Professor of Medicine, University of Arizona**

Dr. Daniel D. Von Hoff, a medical oncologist, oncology drug developer and TGen’s physician-in-chief and director of translational research, will play a leading role at the Ronald A. Matricaria Institute of Molecular Medicine by leveraging his experience in clinical trials for adults to advance therapy development in children.

For more than 30 years, Von Hoff has dedicated his time and experience to the study of cancer and treatment methods. He has served as director of the cancer center and professor of medicine at the University of Arizona and also was the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio. Before that, he was a professor in the Departments of Medicine and Cellular and Structural Biology at the University of Texas Health Science Center, San Antonio.

Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and the laboratory. He and his colleagues were involved in the development of many of the agents we now use routinely, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. At present, he is concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute.

He is currently serving a six-year term on the National Cancer Advisory Board and has served on the FDA’s Oncology Advisory Committee. He also is a past president of the American Association for Cancer Research, served on the AACR and the American Society of Clinical Oncology’s Board of Directors, and is a fellow of the American College of Physicians.

Von Hoff is the founder of *Investigational New Drugs - The Journal of New Anticancer Agents* and is currently editor-in-chief of *Molecular Cancer Therapeutics*. He was the associate editor for two AACR journals, *Clinical Cancer Research* and *Cancer Research*.